CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematologist-oncologists and other healthcare providers involved in the treatment of lung cancer.
  
  OVERVIEW OF ACTIVITY
  The last several years have seen an explosion in the emergence of new therapies, including targeted therapies and immunotherapies, that have transformed the treatment of metastatic non-small cell lung cancer. Although these therapies have been shown to improve overall survival, they have also led to changes in the prevailing treatment algorithms and new challenges in the management of this disease. In order to offer optimal patient care, clinicians must be well informed of these advances.
  
  To provide clinicians with therapeutic strategies to address the disparate needs of patients with metastatic lung cancer, the Visiting Professors audio series takes an innovative case-based approach that couples the perspectives of leading lung cancer investigators with those of general oncologists as they explore the intricacies of making treatment decisions. Upon completion of this CME activity, medical oncologists should be able to formulate an up-to-date and more complete approach to the care of these patients.
  
  LEARNING OBJECTIVES

  • Consider performance status, prior therapeutic exposure, disease-free interval and other patient- or disease-related factors in the selection of systemic therapy for patients with metastatic non-small cell lung cancer (NSCLC).
  • Recall available and emerging data evaluating anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for NSCLC, and determine how to optimally integrate these agents into the management of metastatic NSCLC.
  • Evaluate available clinical trial data documenting the efficacy of angiogenesis inhibitors in patients with metastatic NSCLC, and determine how these agents can be optimally integrated into lung cancer clinical practice.
  • Assess clinical investigator perspectives regarding the safety of immune checkpoint inhibitors for patients with NSCLC, including those with preexisting autoimmune disorders, and consider this information when designing treatment plans.
  • Appraise available research on the benefits of early palliative care for patients with metastatic NSCLC, and integrate this information, as appropriate, into patient consultations.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Clinical Investigators
  
  Benjamin Levy, MD
  Associate Professor, Johns Hopkins School of Medicine
  Clinical Director
  Medical Director, Thoracic Oncology Program
  Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial
  Washington, DC
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Lilly, Merck, Takeda Oncology; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation.
  
  Leora Horn, MD, MSc
  Associate Professor of Medicine
  Clinical Director, Thoracic Oncology Research Program
  Assistant Vice Chairman for Faculty Development
  Vanderbilt University Medical Center
  Nashville, Tennessee
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech, Incyte Corporation, Pfizer Inc, Tesaro, Xcovery; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Xcovery.
  
  Consulting Oncologists
  
  Raymond Lobins, DO
  Hulston Cancer Center (CoxHealth)
  Springfield, Missouri
  
  No relevant conflicts of interest to disclose.
  
  Yanjun Ma, MD
  Tennessee Oncology
  Murfreesboro, Tennessee
  
  No relevant conflicts of interest to disclose.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from Lilly.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: July 2019
  Expiration date: July 2020